1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

  • August 2014
  • -
  • GlobalData
  • -
  • 218 pages

Summary

Table of Contents

PharmaPoint: Asthma - 5EU Drug Forecast and Market Analysis to 2023

Summary

Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline.

The 2013 base-year market sales of asthma products in France were $918m.The relatively slow growth of the German market compared with the French, Spanish, and UK markets is attributable to the slightly decreasing prevalence of asthma in this country over the forecast period. . Advair’s active patent on the Diskus delivery platform in Italy has already expired, but still generates high sales numbers due to the difficulties involved in replicating the delivery technology. GlobalData believes that Advair will slowly lose its dominant position in the Spanish market. GlobalData expects Breo Ellipta to dominate the branded segment of the UK ICS/LABA market, as it is the first complete regimen to be dosed once daily for asthma treatment.

Scope

- Overview of Asthma including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU (the UK, France, Italy, Spain, Germany) from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the 5EU Asthma market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return.
- Stay ahead of the competition by understanding the changing competitive landscape for Asthma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
- Make more informed business decisions from insightful and in-depth analysis of drug performance.
- Obtain sales forecast for drugs from 2013-2023 in 5EU (the UK, France, Italy, Spain, Germany).

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Targeted Therapies in Asthma - 2017

Targeted Therapies in Asthma - 2017

  • $ 8355
  • Industry report
  • February 2017
  • by Firstword Pharma

Description As new targeted asthma therapies emerge, is time running out for Xolair? Xolair’s unique position in the targeted asthma treatment market is under threat. Teva’s Cinqair and GSK’s Nucala ...

Asthma Treatment Drugs Markets in China

Asthma Treatment Drugs Markets in China

  • $ 4000
  • Industry report
  • March 2017
  • by Asia Market Information & Development Company

China’s demand for Asthma Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed ...

Acute Asthma Global Clinical Trials Review, H1, 2017

Acute Asthma Global Clinical Trials Review, H1, 2017

  • $ 2500
  • Industry report
  • February 2017
  • by GlobalData

Acute Asthma Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Acute Asthma Global Clinical Trials Review, H1, 2017" provides an overview of Acute Asthma clinical ...


ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.